Humonix Biosciences Appoints Karen Torrejon, PhD, as New Chief Executive Officer

BioSpace | 2024-05-02 | 翻译由动脉网AI生成，点击反馈



可切换为仅中文







Dr. Torrejon, the original founder of Humonix, replaces Kimberly Southern

Humonix的原始创始人Torrejon博士取代了Kimberly Southern

ALBANY, NY / ACCESSWIRE / May 2, 2024 / Humonix Biosciences, Inc. ('Humonix'), a specialty pharmaceutical research company focused on 3D human tissue models capable of mimicking disease states for pharmaceutical and biotechnology clients, today announced the appointment of Dr. Karen Torrejon as the new Chief Executive Officer.

纽约州奥尔巴尼/ACCESSWIRE/2024年5月2日/Humonix Biosciences，Inc.（“Humonix”）是一家专注于3D人体组织模型的专业制药研究公司，能够为制药和生物技术客户模拟疾病状态，今天宣布任命Karen Torrejon博士为新任首席执行官。

Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform expanding research offerings for industry clients..

最初于2014年创建该公司的Torrejon博士现在将领导该公司，因为它将转变为一个更广泛的，科学驱动的平台，为行业客户扩展研究产品。。

Humonix's platform has been built upon a proprietary 3D human tissue-based system, originally introduced for the study of glaucoma under the Glauconix name, that has now scaled to encompass multiple disease entities including retinal vascular disease, pulmonary fibrosis, and renal fibrosis. As a partner to pharmaceutical and biotechnology companies, Humonix serves to improve the drug development process by expediting the translation of preclinical research into human efficacy using validated human tissue models to predict potential future effect, reducing cost, and improving a program's probability of success.

Humonix的平台是建立在一个专有的基于3D人体组织的系统上的，该系统最初是以青光眼的名义用于青光眼的研究，现在已经扩展到包括多种疾病实体，包括视网膜血管疾病，肺纤维化和肾纤维化。作为制药和生物技术公司的合作伙伴，Humonix通过使用经过验证的人体组织模型加速临床前研究转化为人体功效，以预测潜在的未来效果，降低成本，提高项目成功的可能性，从而改进药物开发过程。

Importantly, Humonix's ex vivo system enriches the understanding of mechanisms underlying therapeutic efficacy while reducing the need for animal testing in line with the FDA's Modernization Act 2.0..

重要的是，Humonix的离体系统丰富了对治疗效果潜在机制的理解，同时根据FDA的现代化法案2.0减少了对动物测试的需求。。

'I am excited to once again lead the company that I founded a decade ago as we now expand into broader disease models as Humonix Biosciences,' said Dr. Torrejon. 'I am grateful to Ms. Southern for having helped Glauconix gain a foothold in the contract research space, and I'm truly excited to propel this company forward as Humonix to expand our scientific platform systematically.

托雷琼博士说：“我很高兴能够再次领导我十年前创建的公司，现在我们正在扩展到更广泛的疾病模型，如Humonix Biosciences。”我非常感谢Southern女士帮助Glauconix在合同研究领域站稳脚跟，我真的很高兴能推动这家公司作为Humonix系统地扩展我们的科学平台。

Our ability to test compounds in human tissues ex vivo sets us apart in enabling the early selection of ideal candidates for further development.'.

我们在离体人体组织中测试化合物的能力使我们能够尽早选择理想的候选物进行进一步开发。”。

'We would like to thank Ms. Southern for her exemplary service to the company,' said Richard Frederick, Chairman of the Humonix Board. 'We are thrilled to have Dr. Torrejon once again guiding Humonix as its scientific visionary. We look forward to expanding into new areas of research, enabling incredible value creation for industry partners and inevitably for patients, alike.'.

Humonix董事会主席理查德·弗雷德里克（RichardFrederick）说，我们要感谢Southern女士为公司做出的杰出贡献我们很高兴Torrejon博士再次指导Humonix成为其科学远见者。我们期待着扩展到新的研究领域，为行业合作伙伴和患者创造难以置信的价值。”。

'The Board is truly excited to leverage Dr. Torrejon's unparalleled scientific prowess to lead Humonix,' said Barbara Wirostko, MD, FARVO, Adjunct Professor of Ophthalmology at the University of Utah, Chief Medical Officer of Qlaris Bio, Inc., and Humonix Board Member. 'The ability of this platform to translate preclinical research into clinical efficacy offers immense opportunities to clients and ultimately to patients.'.

犹他大学眼科副教授、Qlaris Bio，Inc.首席医学官兼Humonix董事会成员Barbara Wirostko医学博士FARVO说：“董事会非常高兴能够利用Torrejon博士无与伦比的科学才能来领导Humonix。”该平台将临床前研究转化为临床疗效的能力为客户并最终为患者提供了巨大的机会。”。

About Humonix Biosciences, Inc.

关于Humonix Biosciences，Inc。

Humonix Biosciences, Inc. was founded in 2014 in Albany, New York, with the aim to develop 3D human tissue models to mimic diseases in an ex vivo preclinical system. Humonix is focused on reducing the need to rely upon animal testing to predict the translation of preclinical drug or biologic efficacy to humans.

Humonix Biosciences，Inc.于2014年在纽约州奥尔巴尼成立，旨在开发3D人体组织模型，以在离体临床前系统中模拟疾病。Humonix专注于减少依赖动物测试来预测临床前药物或生物功效向人类的转化的需要。

Humonix Biosciences' investors include Excell Partners, Eastern New York Angels and private equity investors as well. For more information, please visit www.humonixbio.com..

Humonix Biosciences的投资者包括Excell Partners、Eastern New York Angels和私募股权投资者。有关更多信息，请访问www.humonixbio.com。。

Media Contact

媒体联系人

George Torrejon

乔治·托雷洪

gtorrejon@humonixbio.com

(631) 487-5553

Contact Information

联系方式

George Torrejon

乔治·托雷洪

Senior Director